<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545114</url>
  </required_header>
  <id_info>
    <org_study_id>0002103</org_study_id>
    <nct_id>NCT02545114</nct_id>
  </id_info>
  <brief_title>Tolvaptan for Patients With Acute Neurological Injuries</brief_title>
  <official_title>Use of Tolvaptan to Treat SIADH-induced Hyponatremia in Selected Patients With Acute Neurological Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyponatremia occurs frequently in patients with acute brain injury in the days to weeks
      following injury, and may contribute to adverse outcome. In addition, hyponatremia can
      aggravate neurologic dysfunction, complicate neurological assessments, and contribute to
      neurologic symptoms such as gait dysfunction that can impair efforts at mobilization and
      rehabilitation. Strict normonatremia (serum Na levels between 135 and 145 meq/dl) is the goal
      in most patients with acute brain injury. SIADH is the most frequent cause of hyponatremia in
      patients with neurological injury; however, treatment with fluid restriction is often
      difficult or contra-indicated, for example in patients with subarachnoid hemorrhage (SAH)
      where intravascular hypovolemia can trigger vasospasms. The aim of this project is to test
      Tolvaptan, an ADH antagonist, as a treatment in selected patients with acute brain injury who
      have developed SIADH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyponatremia occurs frequently in patients with acute brain injury in the days to weeks
      following the acute injury, and may contribute to adverse outcome (1). In addition,
      hyponatremia can aggravate neurologic dysfunction, complicate neurological assessments, and
      contribute to neurologic symptoms such as gait dysfunction that can impair efforts at
      mobilization and rehabilitation. Strict normonatremia (serum Na levels between 135 and 145
      meq/dl) is the goal in most patients with acute brain injury.

      Various studies have shown that SIADH (syndrome of inappropriate anti-diuretic hormone
      secretion) is by far the most frequent cause of hyponatremia in patients with acute
      neurological injuries (1-4). However, the most frequently recommended standard therapies for
      SIADH such as fluid restriction are often impractical, counter-indicated or impossible to
      implement in neurocritical patients. For example, patients admitted for subarachnoid
      hemorrhage (SAH) require maintenance of a euvolemic state to prevent vasospasms; often, high
      volumes of fluid are required to prevent even brief episodes of hypovolemia, as these may
      trigger vasospasms [5-8].

      Thus many patients are treated with hypertonic saline, which is usually effective, but at the
      price of inducing hypervolemia with possible (worsening of) cardiac dysfunction (which also
      occurs very often in patients with acute brain injury, again in particular those with SAH).
      In addition, using hypertonic saline may require central venous access and ICU monitoring,
      preventing transfer to a step-down unit in otherwise stable patients.

      The investigators plan to use Tolvaptan (Samsca), an oral ADH antagonist that promotes
      aquauresis, as an agent to treat neurologically and hemodynamically stable patients with
      acute neurological injuries and suspected SIADH. As this drug is currently approved for
      1-month use in patients with SIADH, and patients with acute brain injury develop transient
      SIADH with a duration of days to weeks, Tolvaptan would in theory be tailor-made for this
      population. However, experience with Tolvaptan in neurocritical patients is very limited.
      Current local hospital protocols call for maintaining normonatremia in all patients with
      acute brain injury (except for patients with brain edema being treated with hypertonic saline
      to induce hypernatremia). Hyponatremia is usually treated with hypertonic saline at this
      time.

      The investigators aim to use Tolvaptan in patients admitted to the neurological ICU who have
      developed SIADH, who have recurrence of hyponatremia after discontinuation of hypertonic
      saline that was initially given to correct hyponatremia, and in neurologically stable
      patients who develop hyponatremia in the days (up to one week) after admission. Tolvaptan
      will be given for a 3 day period, then DC-ed but restarted immediately if sodium levels drop
      below 135 meq. The maximum treatment duration is 14 days.

      A key point of attention will be that the patients receive sufficient fluid intake, either by
      mouth if they are able to eat and drink, via intravenous administration, or a combination of
      both. The minimum fluid intake must be 2500 ml per 24 hours; usually the intake will be
      greater, especially in patients with SAH. Thus fluid intake/fluid administration will be
      closely monitored. In practice, every patient will be on a continuous IV infusion of 80-100
      ml apart from their oral intake.

      Sodium levels will be checked every 4-6 hours, as is already standard practice in patients
      with acute brain injury who develop hyponatremia.

      Primary endpoint: Normalization of sodium levels (level 135-145 meq/dl). Secondary endpoints:
      1. incidence of vasospasms; 2. incidence of pulmonary edema (defined as evidence of edema on
      chest X ray); 3. clinical outcomes, including length of stay in the ICU.

      Safety Liver enzymes will be monitored because a study in patients with autosomal dominant
      polycystic kidney disease, where Tolvaptan was used to slow the progression of the disease,
      reported that prolonged (3 month) administration of high doses (120 mg) of Tolvaptan was
      linked to a (reversible) rise in OT and PT, and in rare cases bilirubin, in some patients
      (9). However, previous studies in patients without polycystic kidney disease using Tolvaptan
      doses up to 60 mg for one year have not reported liver enzyme rises (10-11). The highest dose
      to be used is 45 mg, and the maximum duration will be 2 weeks.

      Tolvaptan is currently used occasionally in daily clinical practice in local neurological
      ICU's. A review of the data on 43 patients (34 SAH, 5 ICH, 2 AIS, 2 post-brain tumor surgery)
      showed that the drug successfully controlled hyponatremia in the patients in whom it was
      used, without side effects being noted (12). Average sodium levels were 129.4 meq before
      treatment and increased to 135.8 meq within 48 hours. Median treatment duration was 5 days
      (average 4.3 days). No significant side effects were noted. Of note, liberal fluid intake was
      ensured in all of these patients.

      Target patient population and number. A total of 80 patients with acute neurological injury;
      a minimum of 30 patients with subarachnoid hemorrhage, 10 patients with intracranial
      hemorrhage, 10 patients with acute ischemic stroke, 10 patients with traumatic brain injury,
      and 10 patients who have undergone elective neurosurgical intervention.

      Inclusion criteria.

        -  Patients with euvolemic or hypervolemic hyponatremia: serum Na &lt;135 meq/dl

        -  Inappropriately high urinary sodium excretion

      Exclusion criteria.

        -  Clinically evident hypovolemic hyponatremia

        -  Recent myocardial infarction or cardiac surgery

        -  Sustained ventricular tachycardia or fibrillation

        -  Systolic blood pressure of less than 90 mm Hg

        -  Serum creatinine concentration of more than 3 mg per deciliter

        -  History of, or biochemical evidence of, liver disease

        -  Serum sodium concentration less than 120 mmol per liter in association with neurologic
           impairment

        -  Urinary tract obstruction

        -  Use of other diuretics (furosemide, burinex, hydrochlorthiazide) that cannot be safely
           discontinued

        -  Concomitant use of hypertonic saline (prior use OK, if hypertonic is stopped within 1
           hour of the first dose of Tolvaptan administration).

        -  History of chronic SIADH or known chronic hyponatremia from other causes (e.g. heart
           failure)

        -  Uncontrolled hypothyroidism or adrenal insufficiency

        -  Severe co-morbidities with life expectancy &lt;6 months

        -  CMO status
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum sodium level</measure>
    <time_frame>1-3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of vasospasms</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pulmonary edema</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hyponatremia</condition>
  <condition>SIADH</condition>
  <arm_group>
    <arm_group_label>Tolvaptan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention arm. Open label, no control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.</description>
    <arm_group_label>Tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with euvolemic or hypervolemic hyponatremia: serum Na &lt;135 meq/dl

          -  Inappropriately high urinary sodium excretion

        Exclusion Criteria:

          -  Clinically evident hypovolemic hyponatremia

          -  Recent myocardial infarction or cardiac surgery

          -  Sustained ventricular tachycardia or fibrillation

          -  Systolic blood pressure of less than 90 mm Hg

          -  Serum creatinine concentration of more than 3 mg per deciliter

          -  History of, or biochemical evidence of, liver disease

          -  Serum sodium concentration less than 120 mmol per liter in association with neurologic
             impairment

          -  Urinary tract obstruction

          -  Use of other diuretics (furosemide, burinex, hydrochlorthiazide) that cannot be safely
             discontinued

          -  Concomitant use of hypertonic saline (prior use OK, if hypertonic is stopped within 1
             hour of the first dose of Tolvaptan administration).

          -  History of chronic SIADH or known chronic hyponatremia from other causes (e.g. heart
             failure)

          -  Uncontrolled hypothyroidism or adrenal insufficiency

          -  Severe co-morbidities with life expectancy &lt;6 months

          -  CMO status
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kees Polderman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hannon MJ, Behan LA, O'Brien MM, Tormey W, Ball SG, Javadpour M, Sherlock M, Thompson CJ. Hyponatremia following mild/moderate subarachnoid hemorrhage is due to SIAD and glucocorticoid deficiency and not cerebral salt wasting. J Clin Endocrinol Metab. 2014 Jan;99(1):291-8. doi: 10.1210/jc.2013-3032. Epub 2013 Dec 20. Erratum in: J Clin Endocrinol Metab. 2014 Mar;99(3):1096. Javadpur, M [corrected to Javadpour, M].</citation>
    <PMID>24248182</PMID>
  </reference>
  <reference>
    <citation>Rahman M, Friedman WA. Hyponatremia in neurosurgical patients: clinical guidelines development. Neurosurgery. 2009 Nov;65(5):925-35; discussion 935-6. doi: 10.1227/01.NEU.0000358954.62182.B3. Review.</citation>
    <PMID>19834406</PMID>
  </reference>
  <reference>
    <citation>Sherlock M, O'Sullivan E, Agha A, Behan LA, Owens D, Finucane F, Rawluk D, Tormey W, Thompson CJ. Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients. Postgrad Med J. 2009 Apr;85(1002):171-5. doi: 10.1136/pgmj.2008.072819.</citation>
    <PMID>19417163</PMID>
  </reference>
  <reference>
    <citation>Sherlock M, O'Sullivan E, Agha A, Behan LA, Rawluk D, Brennan P, Tormey W, Thompson CJ. The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage. Clin Endocrinol (Oxf). 2006 Mar;64(3):250-4.</citation>
    <PMID>16487432</PMID>
  </reference>
  <reference>
    <citation>Diringer MN, Bleck TP, Claude Hemphill J 3rd, Menon D, Shutter L, Vespa P, Bruder N, Connolly ES Jr, Citerio G, Gress D, HÃ¤nggi D, Hoh BL, Lanzino G, Le Roux P, Rabinstein A, Schmutzhard E, Stocchetti N, Suarez JI, Treggiari M, Tseng MY, Vergouwen MD, Wolf S, Zipfel G; Neurocritical Care Society. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care. 2011 Sep;15(2):211-40. doi: 10.1007/s12028-011-9605-9. Review.</citation>
    <PMID>21773873</PMID>
  </reference>
  <reference>
    <citation>Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G; European Stroke Organization. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35(2):93-112. doi: 10.1159/000346087. Epub 2013 Feb 7. Review.</citation>
    <PMID>23406828</PMID>
  </reference>
  <reference>
    <citation>Edlow JA, Samuels O, Smith WS, Weingart SD. Emergency neurological life support: subarachnoid hemorrhage. Neurocrit Care. 2012 Sep;17 Suppl 1:S47-53. Review.</citation>
    <PMID>22932990</PMID>
  </reference>
  <reference>
    <citation>Stocchetti N; Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Triggers for aggressive interventions in subarachnoid hemorrhage. Neurocrit Care. 2011 Sep;15(2):324-8. doi: 10.1007/s12028-011-9597-5.</citation>
    <PMID>21748498</PMID>
  </reference>
  <reference>
    <citation>Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.</citation>
    <PMID>23121377</PMID>
  </reference>
  <reference>
    <citation>Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006 Nov 16;355(20):2099-112. Epub 2006 Nov 14.</citation>
    <PMID>17105757</PMID>
  </reference>
  <reference>
    <citation>Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010 Apr;21(4):705-12. doi: 10.1681/ASN.2009080857. Epub 2010 Feb 25. Erratum in: J Am Soc Nephrol. 2010 Aug;21(8):1407.</citation>
    <PMID>20185637</PMID>
  </reference>
  <reference>
    <citation>Polderman KH, Bajus D, Varon J. Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries. Neurocrit Care 2014 21:S224 (abstract 215).</citation>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyponatremia</keyword>
  <keyword>SIADH, stroke</keyword>
  <keyword>SAH; ICH</keyword>
  <keyword>AIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
    <mesh_term>Trauma, Nervous System</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

